| Cat.No. | Name | Information |
|---|---|---|
| M2562 | ZCL278 | ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM. |
| M6282 | NSC 23766 | NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA. |
| M9356 | AMG-510 (Sotorasib) | AMG-510 (Sotorasib) is a potent KRAS G12C covalent inhibitor. |
| M9428 | MRTX849 (Adagrasib) | MRTX849 (Adagrasib) is a potent, highly selective, oral available KRAS G12C inhibitor. |
| M6748 | GGTI 298 | GGTI 298 is a geranylgeranyltransferase I (GGTase I) inhibitor. |
| M6704 | EHT 1864 2HCl | EHT 1864 is a potent inhibitor of Rac family GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. |
| M5946 | Salirasib | Salirasib is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation. Phase 2. |
| M5481 | CASIN | CASIN is a selective GTPase Cdc42 inhibitor with IC50 of 2 uM. |
| M3885 | 6H05 trifluoroacetate | 6H05 is a selective and allosteric inhibitor of oncogenic K-Ras(G12C). |
| M3663 | K-Ras(G12C) inhibitor 9 | K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C). |
| M2608 | Kobe0065 | Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD, exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. |
| M55031 | BBO-8520 | BBO-8520 is a first-in-class orally active covalent KRAS G12C inhibitor. BBO-8520 inhibits KRASG12C (ON) by locking the GTP-binding protein in state 1, a conformation incapable of binding effectors, thereby inhibiting the downstream signaling of KRASG12C (ON) that promotes cell proliferation. BBO-8520 also rapidly and completely blocks the RAS-RAF1 interaction, returning KRASG12C to its inactive (OFF) state. |
| M52906 | KRpep-2d | KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. |
| M52905 | Rac1 Inhibitor W56 | Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. |
| M52904 | SAH-SOS1A | SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. |
| M49938 | Glecirasib | Glecirasib is a potent, irreversible, orally active KRAS G12C inhibitor for studies related to KRAS G12C-mediated cancers. |
| M49728 | K20 | K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. |
| M49478 | RMC-8839 | RMC-8839 is an orally available, mutant-selective, direct inhibitor of KRAS G13C. |
| M49477 | YL-17231 | YL-17231 is a pan-KRAS mutant oral small molecule inhibitor in combination with the KRAS switch II pocket for studies related to KRAS mutant solid tumors. |
| M49368 | RM-032 | RM-032 is an orally active KRAS inhibitor that covalently binds to KRAS G12C and procyclin A to inhibit RAS pathway signaling and cell proliferation in KRAS G12C tumor cells. |
| M49367 | SML-8-73-1 | SML-8-73-1 is a GDP analog and also a KRAS inhibitor that irreversibly covalently binds to the GTPase active site of KRAS, and its binding rate to KRAS G12C was more than 95% in a 1 mmol/L GDP/GTP environment, and the IC 50 value for the inhibition of the proliferation of lung cancer cells H358 was 26.6 μmol/L . |
| M45215 | ABSK071 | ABSK071 is a novel KRAS G12C inhibitor with antitumor activity. |
| M45162 | BI 1823911 | BI 1823911 is a novel, highly selective, covalently irreversible oral small molecule inhibitor of KRASG12C. |
| M45161 | ARS-3248 | ARS-3248 is a novel KRAS G12C inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
